ArticleHuman cell2025
Robo4 inhibits neovascularization in oxygen-induced retinopathy by regulating ARF6 and VEGF.
Article in Human cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Retinopathy of prematurity (ROP) is an abnormal proliferative disease of retinal blood vessels. This study investigates the role of Robo4 in angiogenesis and its molecular mechanisms in the Oxygen-Induced Retinopathy (OIR) model and a hypoxic injury model of human umbilical vein endothelial cells (HUVECs). In the OIR model, Roundabout 4 (Robo4) expression was significantly decreased, while Robo4 overexpression inhibited neovascularization and alleviated retinal tissue damage. Under hypoxic injury-inducing conditions in HUVECs, Robo4 expression was inhibited, but overexpression enhanced cell proliferation and inhibited angiogenesis by negatively regulating the expression of adenosine diphosphate ribosylation factor 6 (ARF6) and vascular endothelial growth factor (VEGF). Molecular analysis revealed that Robo4 regulates VEGF expression through ARF6. Overexpression of Robo4 reduced ARF6 and VEGF expression, while knocking down Robo4 increased ARF6 and VEGF levels, confirming Robo4's role as a key regulator in the ARF6-VEGF axis. Additionally, Robo4 overexpression significantly inhibited the angiogenic capacity of HUVECs, and ARF6 overexpression partially reversed Robo4-mediated inhibition of angiogenesis. In the OIR model, Robo4 overexpression significantly suppressed pathological neovascularization, as evidenced by a significant reduction in the percentage of non-perfused areas. Furthermore, Robo4 overexpression downregulated ARF6 and VEGF expression levels and promoted the normalization and remodeling of retinal vascular structures. These findings suggest that Robo4 inhibits pathological angiogenesis by regulating ARF6 and VEGF, providing insights into its potential as a therapeutic target for retinal diseases like ROP.
Indexed as
Identifiers
40778968What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.